Small Molecule Regulators Targeting Steroid Receptor Coactivators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for steroid receptor coactivator-related diseases, such as cancer and metabolic disorders, lack effective small molecule inhibitors that can specifically target and regulate steroid receptor coactivators like SRC-1, SRC-2, and SRC-3, which are involved in various pathological conditions.
Innovation Solution
Development of specific steroid receptor coactivator regulators in the form of small molecules that modulate the activity of SRC family proteins, including compounds with defined heterocyclic and aromatic structures, which can be administered to treat or prevent diseases by targeting these coactivators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target steroid receptor coactivators, then therapeutic effectiveness against cancer and metabolic disorders is improved, but the complexity of drug development and molecular structure design increases
Solution Approach 1:
The patent segments the steroid receptor coactivator binding interface into distinct molecular regions, designing small molecules that target specific segments of the coactivator protein. This segmentation allows for simplified molecular structures that still achieve effective binding and therapeutic effects, reducing the overall complexity while maintaining reliability.
Solution Approach 2:
The invention applies local quality by designing small molecules with specific functional groups and structural features that are optimized for binding to particular regions of the steroid receptor coactivators. This localized optimization allows effective targeting without requiring complex overall molecular structures, thus improving therapeutic effectiveness while managing structural complexity.
2Measurement precision
If specific small molecule regulators are designed to modulate SRC-1, SRC-2, and SRC-3 activity, then disease treatment specificity is improved, but the difficulty of detecting and measuring coactivator activity increases
Solution Approach 1:
The patent introduces intermediary molecules that serve as measurable proxies for coactivator activity. These small molecule regulators act as mediators between the coactivators and detectable signals, allowing indirect measurement of coactivator function. This approach enables specific disease treatment monitoring without requiring direct measurement of coactivator activity, thus improving specificity while reducing measurement difficulty.
Solution Approach 2:
The invention replaces complex biochemical measurement systems with simpler detection methods. By designing small molecules that produce detectable signals (such as fluorescence or other measurable properties) when bound to or modulating coactivators, the patent substitutes complex biological assays with more straightforward detection techniques, improving measurement precision while reducing technical difficulty.
Data Source
AI summary
Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.